Clinical Trial Finder

Adult Cohorts.

Inclusion Criteria:

• - Age ≥18 and ≤75.

• - A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria.

• - Diagnosis of DM, ASyS, IMNM.

• - Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography.

• - Presence of muscle weakness.

Other protocol-defined criteria apply.

Exclusion Criteria:

• - Contraindication to leukapheresis.

• - History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites.

• - Active infection requiring medical intervention at screening.

• - Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.

• - Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures.

• - Significant lung or cardiac impairment.

• - Previous CAR T cell therapy.

• - Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.

Other protocol-defined criteria apply. Juvenile Cohort.

Inclusion Criteria:

• - Age ≥6 and ≤17 years at enrollment.

• - A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria.

• - Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography.

Other protocol-defined criteria apply.

Exclusion Criteria:

• - Contraindication to leukapheresis.

• - History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites.

• - Active infection requiring medical intervention at screening.

• - Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.

• - Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures.

• - Significant lung or cardiac impairment.

• - Previous CAR T cell therapy.

• - Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.

Other protocol-defined criteria apply.

Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.

Arms

Experimental: CABA-201

DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide preconditioning in subjects with JIIM.

Interventions

Biological: - CABA-201 following preconditioning with fludarabine and cyclophosphamide

Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide